CLINICAL STUDIES WITH CURCUMIN
Curcumin has long been expected to be a therapeutic or preventive agent for several major human diseases because of its antioxidative, anti-inflammatory, and anticancerous effects. In phase I clinical studies, curcumin with doses up to 3600–8000 mg daily for 4 months did not result in discernible toxicities except mild nausea and diarrhea. The pharmacokinetic studies of curcumin indicated in general a low bioavailability of curcumin following oral application. Nevertheless, the pharmacologically active concentration of curcumin could be achieved in colorectal tissue in patients taking curcumin orally and might also be achievable in tissues such as skin and oral mucosa, which are directly exposed to the drugs applied locally or topically.
Unable to display preview. Download preview PDF.
- 3.3. B. B. Aggarwal, A. Kumar, and A. C. Bharti, Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23, 363–398.Google Scholar
- 5.5. R. A. Sharma, A. J. Gescher, and W. P. Steward, Curcumin: The story so far. Eur J Cancer 41, 1995–1968 (2004).Google Scholar
- 6.6. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., Shen, T. S., Ko, J. Y., Lin, J. T., Lin, B. R., Wu, M. S., Yu, H. S., Jee, S. H., Chen, G. S., Chen, T. M., Chen, C. A., Lai, M. K., Pu, Y. S., Pan, M. H., Wang, Y. J., Tsai, C. C., and Hsieh, C. Y., 2001, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high–risk or pre–malignant lesions. Anticancer Res 21, 2895–2900.PubMedGoogle Scholar
- 7.7. R. A. Sharma, H. R. McLelland, K. A. Hill, C. R. Ireson, S. A. Euden, M. M. Manson, M. Pirmohamed, L. J. Marnett, A. J. Gescher, and W. P. Steward, Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7(7), 1894–1900 (2001).PubMedGoogle Scholar
- 8.8. R. A. Sharma, S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, M. Pirmohamed, A. J. Gescher, and W. P. Steward, Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 10(20), 6847–6854 (2004).PubMedCrossRefGoogle Scholar
- 10.10. G. Garcea, D. J. Jones, R. Singh, A. R. Dennison, P. B. Farmer, R. A. Sharma, W. P. Steward, A. J. Gescher, and D. P. Berry, Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90(5), 1011–1015 (2004).PubMedCrossRefGoogle Scholar
- 11.11. G. Garcea, D. P. Berry, D. J. Jones, R. Singh, A. R. Dennison, P. B. Farmer, R. A. Sharma, W. P. Steward, and A. J. Gescher, Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14(1), 20–125 (2005).Google Scholar
- 12.12. S. D. Deodhar, R. Sethi, and R. C. Srimal, Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71, 632–634.Google Scholar
- 19.19. J. S. James, Curcumin: Clinical trial finds no antiviral effect. AIDS Treat News 242, 1–2 (1996).Google Scholar